CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


hydroxychloroquine in combination with camostat mesylateWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)


Name (Synonyms) Correlation
drug113 Best Practice Wiki 1.00
drug393 Hydroxychloroquine in combination of Azithromycin Wiki 1.00
drug854 Tocilizumab Wiki 0.25

Correlated MeSH Terms (7)


Name (Synonyms) Correlation
D007676 Kidney Failure, Chronic NIH 1.00
D020521 Stroke NIH 0.71
D003324 Coronary Artery Disease NIH 0.71
D029424 Pulmonary Disease, Chronic Obstructive NIH 0.58
D008173 Lung Diseases, Obstructive NIH 0.50
D009369 Neoplasms, NIH 0.38
D007239 Infection NIH 0.08

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 An Open-Label Study to Compare the Efficacy, Safety, and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to "no Treatment" in Hospitalized Patients Suffering From a Mild or Moderate SARS CoV 2 Virus

Patients with COVID-19 which are 60 years old or above or with comorbidities are at risk of deteriorating and developing severe illness. This prospective open label study will include people 60 years old or above or younger if at risk for severe disease. Individuals confirmed to have SARS-CoV-2 infection will be identified using medical records screening. They will then be offered to participate in the study and if agree will be given the informed consent. After examining inclusion and exclusion criteria they will be asked to sign the informed consent and after signing Information like immunizations, ECG results, diagnostic images and reports, written medical reports, diagnostic lab testing results (e.g. blood tests, urine tests, blood bank info), allergies and intolerances (drug and food allergies, food intolerances), prescription history, and general patient information (e.g. name, birthdate, personal health number, address, phone number) will be gathered. Those who are not eligible for the study will be informed of the reason(s) for ineligibility (generally it will be a safety exclusion and they should be aware of this). Those who are eligible will be randomized to one of three arms: hydroxychloroquine + azithromycin, hydroxychloroquine + camostat mesylate or "doing nothing" in a ratio of 2:1:2. Study drug will be dispensed by the hospital pharmacy. Follow up will continue for 8 weeks.

NCT04355052 COVID - 19 Drug: hydroxychloroquine in combination with camostat mesylate Drug: Hydroxychloroquine in combination of Azithromycin

Primary Outcomes

Description: the clinical state of the patient regarding respiratory state as defined by the NEWS scoring system

Measure: clinical state as reflected by NEWS scoring

Time: 7 days

Description: positive PCR SARS COVID 2 in the respiratory system

Measure: positive PCR

Time: 7 days

Secondary Outcomes

Description: prevention of hospitaliztion in the ICU

Measure: prevention of ICU

Time: 14 days

Description: prevention of assisted ventilation

Measure: prevention of assisted ventilation

Time: 14 days

Description: prevention of Extracorporeal Membrane Oxygenation (ECMO)

Measure: prevention of ECMO

Time: 14 days

Description: death

Measure: death

Time: 14 days

Description: positive PCR SARS COVID 2 in the respiratory system

Measure: positive PCR

Time: 14 days

Other Outcomes

Description: death

Measure: death

Time: 60 days


No related HPO nodes (Using clinical trials)